BRIEF-Kyprolis (Carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma

* KYPROLIS® (CARFILZOMIB) EXTENDED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN PHASE 3 ASPIRE TRIAL
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.